News

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated at go-forward dose Registrational Phase 3 study of vopimetostat plus daraxonrasib as front-line treatment for patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Data from vo

Yahoo·07:00TNGX▲+6.9%

Tango Therapeutics Q3 EPS $(0.39) Misses $(0.35) Estimate

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 378.57 percent decrease over earnings of $0.14 per share

Benzinga·03:36TNGX▲+6.9%

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

The study is evaluating the combination in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant non-small cell lung cancerBOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer and Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoveri

Yahoo·08:30TNGX▲+6.9%

Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the

Yahoo·07:00TNGX▲+6.9%

Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity

SeekingAlpha·03:08TNGX▲+6.9%

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.

Benzinga·02:22TNGX▲+6.9%

Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus

Tango Therapeutics (TNGX) has drawn fresh attention after reporting updated Phase 1/2 data for vopimetostat combined with RAS(ON) inhibitors in MTAP-deleted, RAS-mutant pancreatic and lung cancers, alongside plans for a global registrational trial. The share price reaction has been choppy around the news. Tango Therapeutics is up 3.13% on a 1-day share price return to US$22.89 but down 9.35% over 7 days and 8.15% over 30 days, while the year-to-date share price return of 156.33% and 1-year...

Yahoo·13:11TNGX▲+6.9%

Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer. Read more on TNGX stock here.

SeekingAlpha·12:15

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer - Slideshow

SeekingAlpha·09:01TNGX▲+6.9%

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.

Yahoo·10:41TNGX▲+6.9%